SYLDESTA Canadian Trademark Information
Human pharmaceutical preparations for the treatment and prevention of cardiovascular diseases, pain, central nervous system diseases and disorders, namely, encephalitis, epilepsy, neuropathic pain, Alzheimer's disease, cerebral palsy, Parkinson's disease, Huntington's disease, dementia, depression, bi-polar disorder, stroke, anti-psychotic preparations, headaches and migraine, cancer, inflammation and inflammatory diseases, namely, rheumatoid arthritis, Crohn's disease, multiple sclerosis (MS), psoriasis, scleroderma, inflammatory bowel diseases, irritable bowel syndrome, colitis, pelvic inflammatory disease, chronic pelvic pain, inflammatory connective tissue diseases, respiratory and infectious diseases, namely, eye infections, skin infections, intra-abdominal infections, and urinary tract infections namely cystitis and prostatitis, gastro-intestinal disorders, auto-immune diseases, metabolic diseases and disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy; and opthalmic pharmaceutical preparations.
Perfect for these industries
Words that describe this mark
human pharmaceutical preparations treatment prevention cardiovascular diseases pain central nervous diseases disorders encephalitis epilepsy neuropathic pain alzheimers disease cerebral palsy parkinsons disease huntingtons disease dementia
Abandonment Notice!
On Wednesday, October 31, 2018,
status on the SYLDESTA
trademark changed to Interruption of proceeding.
Apply Now for this name starting at $449!
CAUTION: Although Canada registration for this particular filing is inactive,
the mark may still enjoy common law rights, or may have been applied for again in a separate application.
Further research may be warranted to determine where this mark is truly abandoned in commerce.
On Monday, June 21, 2010, a canadian trademark registration was filed for
SYLDESTA by Johnson & Johnson
a legal enti *********, **********, ***** ****.
The Canadian IP office has given the trademark application number of
1486036.
The current status of this trademark filing is Interruption of proceeding.
The correspondent listed for
SYLDESTA is
GOWLING WLG (CANADA) LLP of *********, **********, ***** ****
The SYLDESTA
trademark is filed in the description of
Human pharmaceutical preparations for the treatment and prevention of cardiovascular diseases, pain, central nervous system diseases and disorders, namely, encephalitis, epilepsy, neuropathic pain, Alzheimer's disease, cerebral palsy, Parkinson's disease, Huntington's disease, dementia, depression, bi-polar disorder, stroke, anti-psychotic preparations, headaches and migraine, cancer, inflammation and inflammatory diseases, namely, rheumatoid arthritis, Crohn's disease, multiple sclerosis (MS), psoriasis, scleroderma, inflammatory bowel diseases, irritable bowel syndrome, colitis, pelvic inflammatory disease, chronic pelvic pain, inflammatory connective tissue diseases, respiratory and infectious diseases, namely, eye infections, skin infections, intra-abdominal infections, and urinary tract infections namely cystitis and prostatitis, gastro-intestinal disorders, auto-immune diseases, metabolic diseases and disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy; and opthalmic pharmaceutical preparations.
.
100% Satisfaction Guarantee
protect your valuable brand now.
Classification Information